全文获取类型
收费全文 | 1440篇 |
免费 | 128篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 10篇 |
儿科学 | 55篇 |
妇产科学 | 13篇 |
基础医学 | 154篇 |
口腔科学 | 21篇 |
临床医学 | 179篇 |
内科学 | 383篇 |
皮肤病学 | 23篇 |
神经病学 | 103篇 |
特种医学 | 164篇 |
外科学 | 117篇 |
综合类 | 133篇 |
一般理论 | 3篇 |
预防医学 | 65篇 |
眼科学 | 24篇 |
药学 | 49篇 |
中国医学 | 1篇 |
肿瘤学 | 87篇 |
出版年
2021年 | 14篇 |
2019年 | 16篇 |
2018年 | 21篇 |
2017年 | 17篇 |
2016年 | 15篇 |
2015年 | 28篇 |
2014年 | 37篇 |
2013年 | 44篇 |
2012年 | 68篇 |
2011年 | 44篇 |
2010年 | 47篇 |
2009年 | 54篇 |
2008年 | 56篇 |
2007年 | 44篇 |
2006年 | 38篇 |
2005年 | 36篇 |
2004年 | 38篇 |
2003年 | 36篇 |
2002年 | 34篇 |
2001年 | 32篇 |
2000年 | 26篇 |
1999年 | 30篇 |
1998年 | 54篇 |
1997年 | 44篇 |
1996年 | 36篇 |
1995年 | 29篇 |
1994年 | 33篇 |
1993年 | 29篇 |
1992年 | 24篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 36篇 |
1988年 | 34篇 |
1987年 | 48篇 |
1986年 | 34篇 |
1985年 | 43篇 |
1984年 | 24篇 |
1983年 | 23篇 |
1982年 | 30篇 |
1981年 | 15篇 |
1980年 | 17篇 |
1979年 | 27篇 |
1978年 | 24篇 |
1977年 | 13篇 |
1976年 | 21篇 |
1975年 | 17篇 |
1974年 | 10篇 |
1973年 | 11篇 |
1972年 | 11篇 |
1970年 | 9篇 |
排序方式: 共有1584条查询结果,搜索用时 15 毫秒
61.
62.
63.
B Boneu M R Buchanan C Caranobe A M Gabaig D Dupouy P Sie J Hirsh 《Thrombosis research》1987,46(6):845-853
In previous studies, we have reported that standard heparin (SH) was cleared by two mechanisms, a saturable mechanism which predominated at low doses (<100 anti-factor Xa U/kg) and a non-saturable mechanism which predominated at higher doses, when the first mechanism became saturated. In this study, we examined the importance of these two mechanisms in the disappearance of a low molecular weight heparin fraction (LMWH) (CY 216), by comparing the pharmacokinetics and the pharmacodyna-mics of a wide range of doses of SH and CY 216 (1.5 to 500 anti-factor Xa U/kg) Pharmacokinetics was measured as the disappearance of 125I-radiolabelled SH or CY 216. Pharmacodynamics was measured as the disappearance of the anti-factor Xa activity of SH and CY 216. We found that the saturable mechanism contributed little to the disappearance of CY 216 and that it was cleared predominantly by the non-saturable mechanism at all doses tested. Thus, at low doses (<100 anti-factor Xa U/kg), SH was cleared more rapidly than CY 216, whereas at higher doses, CY 216 was cleared more rapidly than SH. We conclude that the mechanism of disappearance of LMWH's differ significantly from those of SH, and that this difference may explain the apparent prolonged anticoagulant activity of LMWH's within the therapeutic range doses. 相似文献
64.
B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells 总被引:8,自引:1,他引:8
Uckun FM; Fauci AS; Heerema NA; Song CW; Mehta SR; Gajl-Peczalska K; Chandan M; Ambrus JL 《Blood》1987,70(4):1020-1034
The purpose of this study was to analyze the expression of B cell growth factor (BCGF) receptors and to elucidate the biologic effects of biochemically purified natural BCGF at the B cell precursor stage of human B lineage lymphoid differentiation. The specific binding of radioiodinated high-mol-wt BCGF (125I-HMW-BCGF) and low-molecular-wt BCGF (125I-LMW-BCGF) to fresh marrow blasts from B cell precursor acute lymphoblastic leukemia (ALL) patients was initially investigated. The estimated number of radioiodinated BCGF molecules bound per blast ranged from undetectable to 24.3 X 10(3) for HMW-BCGF, and from 11.5 X 10(3) to 457.8 X 10(3) for LMW-BCGF. In 3H-TdR incorporation assays, 75% of cases showed a significant response to LMW-BCGF with a median stimulation index of 9.3. By comparison, only 33% of cases showed a significant response to HMW-BCGF with a median stimulation index of 2.4. Subsequently, B cell precursor colony assays were performed to assess and compare the biologic effects of BCGF on leukemic B lineage lymphoid progenitor cells. Among 28 cases studied, 57% responded to both HMW-BCGF and LMW-BCGF, 21% responded only to LMW-BCGF, and the remaining cases showed no proliferative response to either growth factor. The response patterns of virtually pure populations of FACS- sorted leukemic B cell precursors were essentially identical to the proliferative responses of unsorted leukemic B-cell precursors. Synergistic effects between HMW-BCGF and LMW-BCGF were observed in 80% of the cases that responded to both. The numbers of cell-bound radioiodinated BCGF molecules, the stimulation indices, as well as the number of B cell precursor colonies in BCGF-stimulated cultures showed a marked interpatient variation. Patients with structural chromosomal abnormalities (SCAs) involving 12p11-13 or patients with a Philadelphia chromosome showed a greater HMW-BCGF response at the level of leukemic progenitor cells than did other patients (P = .02). The LMW-BCGF response was significantly greater for patients with SCA than for patients without SCA (P = .04). The response of leukemic progenitor cells to HMW-BCGF or LMW-BCGF did not correlate with sex, age, disease status, FAB morphology, WBC at diagnosis, or immunophenotype. To our knowledge, this study represents the first detailed analyses of BCGF receptor expression and BCGF effects in B cell precursor ALL. The data presented provide direct evidence for the expression of functional receptors for both HMW-BCGF and LMW-BCGF in B cell precursor ALL. 相似文献
65.
66.
67.
Brian Dale John W. Eikelboom Jeffrey I. Weitz Ed Young Jeremy S. Paikin Michiel Coppens Richard P. Whitlock Stuart J. Connolly Jeffrey S. Ginsberg Jack Hirsh 《Journal of thrombosis and thrombolysis》2013,35(2):295-301
Compared with warfarin, dabigatran is associated with less intracranial hemorrhage, but an increased risk of myocardial infarction. To explore these phenomena, we compared their effects on thrombin generation. Thrombin generation in plasma from 10 patients taking therapeutic doses of warfarin (mean INR 2.6) was compared with that in plasma containing 250 ng/mL dabigatran. Although lag times were similar when thrombin generation was induced by recalcification or with a range of tissue factor concentrations, there was a greater reduction in peak thrombin generation and endogenous thrombin potential in plasma from warfarin-treated patients than in dabigatran-containing plasma. Similar results were obtained when thrombin generation was determined in plasma samples from 18 warfarin or 36 dabigatran treated patients entered into the RE-LY trial. Warfarin suppresses thrombin generation more efficiently than dabigatran. Greater suppression of normal hemostatic mechanisms in the brain and pathological thrombosis at sites of atherosclerotic plaque disruption may explain the higher rate of intracranial bleeding and lower rate of myocardial infarction with warfarin compared with dabigatran. 相似文献
68.
69.
70.